Latest: List of Top 10 Most Concerned Drugs

Every New Year is accompanied by the hope of new drug approval.

Recently, Fierce Pharma has forecasted global drug sales in 2026, and selected the ten most anticipated new drug approvals in 2021.

Top ten new drugs most anticipated to be launched in 2021

These drug candidates are accompanied by various controversies, people's expectations, ambitions to end the epidemic, and even the recurrence of the new coronavirus.

Leading the way is the industry's mixed Alzheimer's disease drug candidates-Biogen and Eisai's aducanumab.

Mentioned here is the second place on the list, Novavax's drug candidate new coronavirus (COVID-19) vaccine.

Among the top ten approved drugs, six drug candidates from previous years have reappeared on this year's list.

The FDA issued a surprisingly complete response letter.

Novartis is expected to respond to the FDA's request in the second or third quarter, but it is unclear whether the FDA will eventually inspect the plant.

Novartis is not the only 2020 drugmaker on the list last year that suffered an accident.

For example, Gilead Sciences abandoned its JAK inhibitor filgotinib for rheumatoid arthritis, while BioMarin's hemophilia A gene therapy valoctocogene roxaparvove remained stagnant after the FDA issued a full response letter.

AstraZeneca (AstraZeneca) and FibroGen's blockbuster anti-anemia drug roxadustat (roxadustat) are also still waiting for a new review date in March.

There is no doubt that the 2021 drug candidates are expected to avoid this fate of uselessness, but even if there is no pandemic, we will look back next year to something that has not been hyped.